This study tests whether adding acalabrutinib to standard rituximab therapy is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The 12 participants receive both drugs to see if the combination …
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated May 17, 2026 05:35 UTC